Medical Oncology

, Volume 18, Issue 4, pp 277–283 | Cite as

Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy

  • Jameela Al-Salman
  • Hyamen Salib
  • Pricha Boonswang
Case Report


The clinical course of follicular lymphoma (FL) is well known. Although it is a chemosensitive disease, thereby allowing substantial palliation, recurrence is the rule; only a small subset who presents with limited stage disease is cured. Multiple attempts have been made over the past two decades to improve the survival of patients with FL, and a large number of phase III trials have been reported. These have included a variety of different therapeutic interventions, such as combination chemotherapy, recombinant interferons, new cytotoxic drugs, and immunologic agents. Most studies have not demonstrated that the use of a particular therapy convincingly prolongs survival. Follicular lymphoma cells express CD20 and are associated in most cases with the t(14:18) chromosomal translocation. Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen, which has been utilized for the therapy of B-cell non-Hodgkin’s lymphoma. Rituximab was shown to be active in FL, and studies of its effectiveness in combination with cytotoxic chemotherapy to increase the response rate are forthcoming.

Key Words

Follicular lymphoma rituximab gastrointestinal 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rohatiner, A. Z., and Lister, T. A. (1991). New approaches to the treatment of follicular lymphoma. Br. J. Haematol. 79(3):349–354.PubMedGoogle Scholar
  2. 2.
    Peterson B. A. (1999). Current treatment of follicular low grade lymphoma. Semin. Oncol. 26(5; Suppl 14):2–11.PubMedGoogle Scholar
  3. 3.
    Domizio, P., et al. (1993). Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. J. Surg. Pathol. 17(5):429–442.CrossRefGoogle Scholar
  4. 4.
    Contreary, K., Nance, F., and Backer, W. (1989). Primary lymphoma of the gastrointestinal tract. Ann. Surg. 191(5):593–598.CrossRefGoogle Scholar
  5. 5.
    Yoshino, T., et al. (2000). Increased incidence of follicular lymphoma in the duodenum. Am. J. Surg. Pathol. 24(5):688–693.PubMedCrossRefGoogle Scholar
  6. 6.
    Freeman, H. J., Anderson, E. A., and Gascoyne, R. (1997). Clinical, pathological and molecular genetic findings in small intestinal follicle centre cell lymphoma. Can. J. Gastroenterol. 11(1):321–329.Google Scholar
  7. 7.
    Fredman, A., Friedberg, J. W., and Gribben, J. (2000). Highdose therapy for follicular lymphoma. Oncology 14(3):321–329.Google Scholar
  8. 8.
    Foran, J. M., et al. (2000). A UK Multicenter phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109(1):81–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Jonas, C. (1998). Rituxan. The new kid on the block. Oncology Nursing Foundation 24:4.Google Scholar
  10. 10.
    Piro, L. D., White, C. A., Grillo-Lopez, A. J., Janakiraman, N., Saven, A., Beck, T. M., et al. (1999). Ann. Oncol. 10:655–661.PubMedCrossRefGoogle Scholar
  11. 11.
    Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., et al. (1999). Treatment of patientss with low-grade B-cell lymphoma with the combination of chimaeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17:268–276.PubMedGoogle Scholar
  12. 12.
    Link, B. K., Grossbard, M. L., Fisher, R. I., Czuczman, M. S., Gilman, P., Lowe, A. M., et al. (1998). Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP in patients with previously-untreated intermediate-or high-grade non-Hodgkin’s lymphoma. [abstract]. Proc. Am. Soc. Clin. Oncol. 17:7a.Google Scholar
  13. 13.
    Horning, S. J. (2000). Follicular lymphoma: have we made any progress. Ann. Oncol. 11(Suppl.1):S23-S27.CrossRefGoogle Scholar
  14. 14.
    Ghielmini, Hsu, Schmitz, S. F., Burke, K., Pichert, G., Betticher, D. C., et al. (2000). The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol. 11(Suppl 1.):S123-S126.CrossRefGoogle Scholar
  15. 15.
    Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., et al. (2000). J. Clin. Oncol. 18(17):3135–3143.PubMedGoogle Scholar
  16. 16.
    Domizio, P., et al. (1993). Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. J. Surg. Pathol. 17(5):429–442.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  • Jameela Al-Salman
    • 2
    • 1
  • Hyamen Salib
    • 2
    • 1
  • Pricha Boonswang
    • 2
    • 1
  1. 1.MCP-Hahnemann UniversityPhiladelphia
  2. 2.Easton HospitalEaston

Personalised recommendations